Tuesday, 26 September 2023 06:30 GMT

Emyria Hails Ethics Approval For MDMA-Assisted Clinical Trial

(MENAFN- News Direct) Emyria Ltd (ASX:EMD) MD Michael Winlo speaks with Proactive after the company received Human Research Ethics Committee (HREC) approval to conduct its ground-breaking MDMA-assisted clinical therapy for patients with Post-Traumatic Stress Disorder (PTSD). The trial, known as EMDMA-001, will be a 12-month, open-label study conducted in partnership with PAX Centre, one of Australia's leading trauma-focused, multi-disciplinary psychiatric services specialising in the treatment of complex trauma.


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.